**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 16629**

**Manuscript Type: Review**

**Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications**

Hauser P *et al*. Psychiatric and SUD co-morbidities and hepatitis C

**Peter Hauser, Shira Kern**

**Peter Hauser,** VISN 22 Network Office, Long Beach, CA 90822, United States

**Peter Hauser,** Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA 92697, United States

**Peter Hauser,** Department of Psychiatry, University of California San Diego, San Diego, CA 92093, United States

**Peter Hauser, Shira Kern,** VA Long Beach Healthcare System, Long Beach, CA 90822, United States

**Author contributions:** Hauser P and Kern S are the sole contributors to this manuscript.

**Conflict-of-interest:** The authors claim no conflict of interest at this time.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Peter Hauser, MD**, VISN 22 Network Offices, 300 Oceangate Avenue, Suite 700, Long Beach, CA 90822, United States. peter.hauser2@va.gov

**Telephone:** +1-562-8268000-2629

**Fax:** +1-562-8262221

**Received:** January 25, 2015

**Peer-review started:** January 26, 2015

**First decision:** March 6, 2015

**Revised:** June 21, 2015

**Accepted:** June 30, 2015

**Article in press:**

**Published online:**

**Abstract**

Chronic hepatitis C virus (HCV) viral infection is the most common blood-borne viral infection and approximately 2%-3% of the world’s population or 170-200 million people are infected. In the United States as many as 3-5 million people may have HCV. Psychiatric and substance use disorders (SUD) are common co-morbid conditions found in people with HCV and are factors in predisposing people to HCV infection. Also, these co-morbidities are reasons that clinicians exclude people from antiviral therapy in spite of evidence that people with HCV and co-morbid psychiatric and SUD can be safely and effectively treated. Furthermore, the neuropsychiatric side effects of interferon (IFN), until recently the mainstay of antiviral therapy, have necessitated an appreciation and assessment of psychiatric co-morbidities present in people with HCV. The availability of new medications and IFN-free antiviral therapy medication combinations will shorten the duration of treatment and exposure to IFN and thus decrease the risk of neuropsychiatric side effects. This will have the consequence of dramatically altering the clinical landscape of HCV care and will increase the number of eligible treatment candidates as treatment of people with HCV and co-morbid psychiatric and SUD will become increasingly viable. While economically developed countries will rely on expensive IFN-free antiviral therapy, less developed countries will likely continue to use IFN-based therapies at least until such time as IFN-free antiviral medications become generic. The current manuscript discusses the efficacy and viability of treating HCV in people with psychiatric and SUD comorbidities, the treatment of the neuropsychiatric side effects of IFN -based therapies and the impact of new medications and new treatment options for HCV that offer the promise of increasing the availability of antiviral therapy in this vulnerable population.

**Key words:** Hepatitis C; Psychiatric disorders; Substance use disorders; Antiviral treatment

# © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis C viral (HCV) is among the most common blood-borne viral infections in the world. Although disease management strategies are often complicated by the high rate of psychiatric and substance use disorders (SUD) within this population, studies now indicate that neuropsychiatric side effects can be effectively managed during antiviral therapy and that individuals with pre-existing psychiatric and SUD can be treated successfully and achieve SVR. Furthermore, the development of new medication options for the treatment of HCV has provided additional opportunities for treatment of people with HCV who have- or are at risk for- psychiatric illness.

Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. *World J Hepatol* 2015; In Press

**HEPATITIS C: AN OVERVIEW**

***Prevalence***

Hepatitis C virus (HCV) is among the most common blood-borne viral infections in the world. Approximately 3% of the world’s population or 170-200 million people are infected, and an estimated 3.2-5.2 million people are infected in the United States[1-3]. HCV is often asymptomatic for a decade or longer after initial infection, and if undiagnosed and untreated, increases the risk of liver fibrosis, cirrhosis, liver cancer, liver failure, and ultimately, death[1].

A study that assessed mortality rates between 1999 and 2004 found that there were a total of 56409 HCV related deaths in the United States during this 5 year period[4]. Over this same time period, mortality rates increased by 123% with a steady increase for those between ages 55 to 64. In the year 2004 alone, 7427 deaths accounted for 148611 years of potential life lost[4]. Furthermore, a subsequent study of 34480 HCV infected individuals and non HCV infected controls showed that HCV infected individuals who initiated or completed treatment, had a significantly reduced risk of mortality[5]. For these reasons, early detection of HCV and prompt antiviral treatment are of the utmost importance. Psychiatric and substance use disorders (SUD) are common co-morbidities among individuals with HCV and are often barriers to antiviral treatment.

***Sources of infection***

Among the most common routes of HCV transmission, intravenous drug use (IVDU) in particular continues to be the most common and contemporary source of infection[6-8]. While much less frequent, HCV can be transmitted through sexual contact, or to infants born from an HCV infected mother[2]. Other routes of transmission are no longer common including blood transfusion, needle stick injuries or non-professionally applied tattoos[9].

**HCV AND HEALTH RELATED QUALITY OF LIFE**

Individuals with gastrointestinal disease in general and HCV in particular have a lower Health Related Quality of Life (HRQOL) than the general population[10,11]. Factors such as poorer work and social adjustment, lower acceptance of illness, higher illness stigma, poorer reported neurocognitive functioning and concentration, and higher levels of subjective physical symptoms are associated with lower HRQOL and are highly correlated with depressive symptomatology in these individuals[12]. Several studies suggest that patients with chronic liver disease (and HCV in particular) also have disproportionately high rates of pain-related diagnoses which may impair their functioning[13-17]. HCV is associated with several medical comorbidities including peripheral neuropathy, arthritis, and fibromyalgia. In one retrospective chart review study of 8224 Veterans with HCV, 67% had co-occurring pain- related diagnoses including arthropathy, low back pain, and/or arthritis and 56% had past or present SUD diagnoses[13]. Additional studies indicate that biopsychosocial factors are significantly related to pain severity and interference, where emotional distress, mood symptoms (such as depression) and sleep disturbance predicted pain severity[14,15,18] (Table 1).

Individuals with HCV have higher rates of depression than those without HCV and also have higher rates of depression when compared to those with other gastrointestinal diseases such as irritable bowel disease **(**IBD) and irritable bowel syndrome (IBS)[10], non-alcoholic fatty liver disease (NAFLD) and hepatitis B virus (HBV)[11]. Individuals with HCV are most likely to have comorbid psychiatric conditions; depression is the most common psychiatric diagnosis among these individuals and is directly related to lower HRQOL[19-22]. One study of 881 Veterans with HCV found that 37% were prescribed an antidepressant medication[22] (Table 2).

Overall, HCV has a negative impact on quality of life and overall functioning[23]. The stigma associated with known infection has a demonstrated effect on HRQOL and is often related to a lack of adequate education on HCV and antiviral treatment[1]. Further efforts to educate both individuals with HCV and treatment providers on the viability of treating those with comorbid psychiatric conditions, and in particular, depression may be of benefit.

**PSYCHIATRIC AND SUD COMORBIDITIES AND TREATMENT**

Treatment issues and disease management strategies are complicated by the extremely high rate of psychiatric and SUD in those who have HCV[19,22,24-29].

Historically, people with HCV and comorbid psychiatric diagnoses were not included in initial research treatment studies for various reasons including the subjective belief that individuals with co-morbid psychiatric and SUD would be less likely to be compliant and therefore not complete treatment, more likely to develop neuropsychiatric side effects (in particular depression), and more likely to be re-infected if they continued IVDU[30,31].

Until recently interferon-based therapies have been the standard of care for HCV treatment. However, these therapies are known to induce depression, among other neuropsychiatric problems including insomnia, irritability and mood changes[27,32-34]. Depression co-morbidity is of particular concern as interferon (IFN) precipitates depression in approximately 20%-30% of individuals who receive IFN-based antiviral therapies[24,27,35]. Those treated with interferon-alpha (IFN**-**α) therapy often develop depressive symptoms, which can lead to reduction in medication dosage or treatment discontinuation, thus reducing the likelihood of antiviral therapy completion or achieving a sustained virologic response (SVR)[27]. IFN- based treatments are also likely to exacerbate preexisting psychiatric conditions including depression and bipolar disorder and in isolated cases, have led to suicidal ideation and suicide attempts[35-37]. The severity of depressive symptoms prior to beginning antiviral therapy but not the diagnosis of past or present major depressive disorder (if adequately treated with antidepressants- see Hauser *et al*, 2009)[39] may be predictive of the onset and severity of depressive symptoms during IFN- based antiviral treatment[24,27,35,38,39](Table 3).

Several studies suggest that individuals with psychiatric and alcohol use disorders (AUDs) are more likely to be considered ineligible for antiviral therapy even though other studies suggest that completion of therapy and achieving SVR among other variables is not different between people with HCV and co-morbid psychiatric disorders from those with HCV without psychiatric and SUD[38,40-43]. One study that compared antiviral completion rates, SVR, emergency room visits and hospitalizations of HCV infected Veterans with pre-existing Major Depressive Disorder (MDD) treated with antidepressants to those without MDD found no differences between groups[38].

People with schizophrenia and co-morbid HCV have also been excluded from IFN-based antiviral therapy despite a higher prevalence of HCV among this group than in the general population[44,45]. However, retrospective chart review studies suggest that people with schizophrenia and co-morbid HCV can be treated safely with ifn-based antiviral therapy and achieve similar SVR rates as those without co-morbid psychiatric disorders and with no greater likelihood of adverse events or emergency room visits[43,46].

Previous studies have also indicated that individuals with SUDs, particularly intravenous drug users (IVDUer) are also underserved and undertreated for fear of decreased compliance and/or risk of reinfection[31]. Although findings are variable, more recent research indicates that treatment completion is viable when these individuals are carefully supervised, and furthermore, that risk of reinfection is minimal, even among those who continue to use IV drugs post- antiviral treatment[31,47,48] (Table 4).

While less common, IFN- based regimens can also induce muscle aches and pain which may only serve to exacerbate depressive symptoms. Neurocognitive and somatic symptoms associated with depression are known to be exacerbated with IFN regimens and, for those with preexisting pain conditions, depression severity may increase pain intensity[14,15,49]. Though somatic symptoms should not be used as a primary predictor of depression severity, pain should be assessed and monitored in relation to cognitive and affective symptoms, when monitoring patients prior to and during treatment for HCV[50].

Overall, the emergence or exacerbation of depressive symptoms is common in IFN-α therapy and can compromise the outcome of HCV treatment[30]. As such, routine screening for psychiatric disorders and early treatment intervention for psychiatric disorders not previously identified are necessary prior to initiation of antiviral therapy[19,51]. Also ongoing routine screening for new onset depression during antiviral therapy is indicated. Furthermore, treatment plans must include monitoring of comorbid psychiatric conditions throughout the course of antiviral therapy[51,52].

Untreated IFN-induced depression may lead to dose reductions and premature IFN therapy termination and in worst case scenarios risk of suicide. However, if well monitored and managed, psychiatric and SUD comorbidities do not pose a significant impediment to treatment completion and compliance[47,51,52].

**DEPRESSION MANAGEMENT DURING IFN-BASED ANTIVIRAL THERAPY**

As mentioned, studies suggest that preexisting psychiatric and SUD should not be regarded as exclusionary to IFN-α therapy. Specific to depression, IFN may induce or exacerbate symptoms of depression but these symptoms can be managed during antiviral therapy and do not prevent/preclude individuals from completing treatment or achieving favorable viral clearance rates[24,36,38,52,53].

Studies suggest that the onset of depressive symptoms during IFN therapy is not predicted by age, gender, past history of major depressive disorder (MDD) or substance use[24,27,35,52]. Some studies suggest that people with higher depressive symptom severity prior to antiviral therapy initiation as well as a family history of MDD are more likely to develop IFN-induced depression. However, open-label studies of antidepressants and specifically selective serotonin reuptake inhibitors (SSRIs) in people who develop IFN-induced depression during antiviral therapy, demonstrate that these medications can be effective in managing depressive symptoms during IFN therapy and allow people to remain on antiviral treatment[24,54,55] (Table 5).

***Antidepressant prophylaxis of patients with HCV who receive antiviral therapy***

Antidepressant prophylaxis may decrease the likelihood of the development of IFN- induced depressive symptoms and MDD in HCV infected patients, particularly those with a past history of IFN- induced MDD, and may increase the rates of treatment compliance and completion[36,56].

One study of people with HCV who failed antiviral therapy due to IFN-induced depression found that citalopram is effective both before and during IFN-α therapy; used as pretreatment for these people with HCV, it helped to reduce the incidence of MDD during the first 6 mo of antiviral treatment as compared with two control groups[57]. As mentioned several studies have shown that, for those who developed MDD during IFN therapy, treatment with SSRIs led to a reduction in depressive symptoms and continuation of antiviral therapy[24,54,55].

In contrast, two double blind, placebo-controlled trials that assessed the benefit of prophylactic treatment (or pre-treatment prior to initiation of antiviral therapy) with paroxetine to prevent development of IFN-induced depression found no benefit as compared with placebo in antiviral treatment naïve people with HCV[58,59]. However, in one of these studies, of 11 patients who developed IFN-induced depression during the study and were then entered into the open- label rescue arm of the study, 10 of 11 had a significant reduction of depressive symptoms that allowed continuation of antiviral treatment[58]. In the second study, assignment to paroxetine did not decrease the likelihood of IFN-induced depression but was associated with a significantly reduced depression symptom severity score. Although sample sizes were small, these results suggest that prophylactic treatment with paroxetine is not effective in preventing the onset of IFN-induced MDD but may have benefits in reducing overall depression symptom severity[58,59].

A more recent double-blind, placebo-controlled trial that assessed the benefit of prophylactic treatment with citalopram in 39 HCV infected patients who did not have significant symptoms of depression prior to initiation of antiviral therapy reported similar results. Randomization to citalopram did not significantly reduce the likelihood of developing IFN-induced depression as compared with placebo[60] (Table 6).

Overall, there is no substantive evidence that antidepressant prophylaxis during antiviral therapy for HCV has significant benefits. Potential benefits must be weighed against the risks of antidepressant use above and beyond their common side effects. The use of SSRIs, which have been associated with an increased incidence of gastrointestinal bleeding in the general population[61], may have adverse consequences in people with HCV who are at higher risk for low platelet count, coagulopathy, and esophageal varices[62]. Furthermore, SSRIs have been associated with retinal hemorrhages in people receiving high- dose IFN therapy for malignant melanoma[63]. Other observations in the general population suggest that mirtazapine and sertraline may increase the likelihood of neutropenia[64].

In summary, the wide-spread use of antidepressants to prevent IFN-induced depression in people receiving IFN-based therapy for HCV is not warranted. A more conservative approach involves screening all patients prior to initiation of antiviral therapy for depression, treating depression prior to beginning antiviral therapy, and proactively monitoring depressive symptomatology at regular intervals during the course of treatment.

***Interdisciplinary team/integrated care***

Optimal care for HCV is an interdisciplinary team approach that involves psychiatric health care providers. Individuals with psychosocial comorbidities are able to successfully complete treatment, when an interdisciplinary team with both medical and psychiatric health support is applied[65]. The early identification of depression during HCV treatment can be achieved using an integrated model of care and can also assist individuals who have both mild or severe psychiatric illness in initiating and completing antiviral treatment[66]. Individuals who receive care from an interdisciplinary team are more likely to complete the evaluation for HCV treatment and start antiviral treatment[67].

**NEW MEDICATION TREATMENT OPTIONS FOR HCV**

The use of new FDA-approved medications for the treatment of HCV has distinct advantages when considering antiviral therapy in people with HCV and co-morbid psychiatric and SUD, in large part, because the duration of antiviral therapy and therefore the period of risk for IFN-induced depression as well as other common neuropsychiatric side effects has been shortened. Moreover, medications in development to treat HCV will eliminate the need for IFN altogether. A review of new FDA-approved medications as well as medications under development and their neuropsychiatric side effects are reviewed briefly- below.

***Telaprevir***

Telaprevir used in combination with peginterferon alpha (PEGIFN**-**α**)** and ribavirin (RBV) has been shown to improve response rates in the treatment of HCV, genotype 1[68,69]. It can be used for those with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with IFN-based therapies, including prior non- responders, partial responders, and relapsers[70].

Despite several known side effects associated with telaprevir, including fatigue, rash, nausea, anemia and influenza like symptoms, changes in mood or depression are not known to be direct side effects of this medication[69]. While depressive symptoms have been noted in some clinical trials, they have not been considered primary adverse events nor have they led to drop out or discontinuation of treatment[68,69,71,72].

Telaprevir in combination with PEGIFN/ RBV is superior to PEGIFN/ RBV alone and has higher SVR (approximately 72% *vs* 50%-60%); it is also known to increase response time[68,69,72,73].

Overall, telaprevir may increase the ability to achieve SVR, without a drastic influence on the side effects profile[68]. The risk of depression is not noted to be increased when using telaprevir in combination with PEGIFN/ RBV (Table 7).

***Boceprevir***

Boceprevir, a medication that is similar to telaprevir, is a potent oral HCV-protease inhibitor that is also used in conjunction with PEGIFN/ RBV for the treatment of patients infected with HCV genotype 1. Studies indicate that rates of SVR are improved significantly when boceprevir is used in combination with PEGIFN/ RBV as compared with PEGIFN/ RBV alone[75,76].

While some side effects (such as anemia) commonly associated with PEGIFN/RBV may be more likely to occur with the addition of boceprevir, side effects associated with PEGIFN/ RBV treatment regimens including dysgeusia, rash, dry skin, headache and flu-like symptoms are no more likely to occur with addition of boceprevir[75-77].

Based on the results of the above studies as well as prescribing information published by the FDA, common psychiatric side effects associated with PEGIFN/RBV are not more likely to occur in patients with the addition of boceprevir[78] (Table 8).

***Simeprevir***

Several studies have assessed the efficacy of simeprevir in combination with PEGIFN/ RBV for the treatment of Hepatitis C. Simeprevir is a HCV NS3/4A protease inhibitor indicated as a component of a combination antiviral treatment for the treatment of HCV[78].

Studies suggest that simeprevir in combination with PEGIFN/ RBV significantly improves rates of SVR as compared with PEGIFN/RBV alone. Studies also suggest that the addition of simeprevir can shorten the duration of antiviral therapy to 24 wk (instead of 48 wk with PEGIFN/RBV alone) without a change in SVR or the side effects profile[79-83].

The most common adverse events found with the use of simeprevir in combination with PEGIFN/RBV include fatigue, headache, pruritus, influenza like illness, nausea and neutropenia[79-81]. However, in these studies there were non-significant differences in frequency of adverse events between groups on simeprevir in combination with PEGIFN/RBV *vs* PEGIFN/ RBV, suggesting the side effects may be attributable to the PEGIFN/RBV[79-82].

Depression was not assessed with symptom rating instruments and noted only by self-report in these studies; overall the rates of self- reported depression were not different between the group that received simeprevir in combination with PEGIFN/ RBV *vs* the group that received PEGIFN/ RBV alone and there were very few subjects who experienced depression as a major contributing factor for discontinuation[79,80].

In summary simeprevir does not increase the risk of side effects attributable to PEGIFN/ RBV and can shorten the duration of antiviral therapy and thus the length of exposure to PEGIFN and presumably side effects associated with peginterferon treatment[81] (Table 9).

***Sofosbuvir***

Sofosbuvir is a HCV nucleotide analog NS5B polymerase inhibitor indicated for the treatment of HCV infection as a component of a combination antiviral treatment regimen; it is recommended to be used with PEGIFN**-**α/RBV or with RBV alone thus excluding the need for IFN altogether[78].

The most common adverse events when used with PEGIFN/RBV combination therapy are fatigue, headache, nausea, insomnia and anemia (similar to those found in other combination therapies with PEGIFN). The most common adverse events (≥ 20%) for sofosbuvir and ribavirin combination therapy are fatigue and headache[84,85].

Overall results indicate that psychiatric issues, including depression, are not significant side effects and are rarely the reason for study drop out or discontinuation[85-87]. However the rates of depression in these studies, when reported, are below the generally accepted rate of IFN– induced depression, which is 20%-30%. While this may reflect the decreased duration of IFN exposure, these lower rates of depression may also be due to relying on patient report of side effects.

In summary, results indicate the sofosbuvir in combination with other medications can lead to an early viral response as well as SVR with a shorter duration of treatment, with and without the use of PEGIFN. Furthermore, sofosbuvir provides an effective treatment with little evidence of psychiatric side effects and overall, is well tolerated. Authors suggest that for most, there is no additional benefit to prolonging treatment beyond 12 wk when using a sofosbuvir based regimen[86].

Previous studies have indicated that the majority of people who develop IFN-induced depression have an onset between 6 and 12 wk after antiviral therapy initiation but approximately one third develop IFN- induced depression after 12 wk of antiviral therapy[38]. Thus it’s possible that the use of sofosbuvir in combination with other therapies or alone, may reduce the risk of onset of depressive symptoms by decreasing or eliminating exposure to PEGIFN (Table 10).

**HCV ANTIVIRAL MEDICATIONS IN DEVELOPMENT**

***ABT-450/r–Ombitasvir and Dasabuvir with ribavirin***

A new medication combination of ABT-450r-/Ombitasvir with Dasabuvir has also been assessed both with and without the addition of RBV. Though not yet FDA approved, this combination has yielded promising results; 95% of previously treated individuals with HCV genotype 1 had SVR after 12 wk of treatment[88].

The most commonly reported adverse events of this combination include headache and fatigue, with secondary effects of pruritus (> 10% of participants) anemia, vomiting, constipation, erythema, neck pain, neutropenia and a decrease in hemoglobin (< 10% of participants). Signs and symptoms of depression are not a significant side effect for this combination treatment and does not contribute to discontinuation or drop out[88].

ABT-450/Ombitasvir and Dasabuvir has also been assessed with the addition of ritonavir, either with RBV or placebo. Those treated with this regimen (both with and without RBV) have SVR rates of between 96.6% and 100% after 12 wk of treatment[89].

The most common adverse events were fatigue and headache, along with nausea and decreased hemoglobin. Participants in the RBV group also experienced insomnia, anemia, rash and increased bilirubin levels (all known to be effects of RBV). Serious adverse events included cellulitis, nephrolithiasis and osteoarthritis, though none were judged to be study drug related or led to discontinuation. Outside of insomnia (noted above) no other psychiatric symptoms were reported for either group, both with and without RBV[89].

Overall, it appears this combination with and without ritonavir and/or RBV, is useful in treating HCV without the use of IFN.

***Daclatasvir***

Daclatasvir is a potent NS5A replication complex inhibitor, and is generally well tolerated in phase 1 and phase 2 trials[90]. It has been used successfully in various HCV genotypes, and in both treatment naïve and non-responder/ relapser populations[90,91]. Daclatasvir has been used in combination with several other medications including PEGIFN/RBV, asunaprevir and sofosbuvir, all of which show varying levels of treatment success, as measured by SVR after 12 and 24 wk of treatment, and in some studies, SVR was obtained after 8 wk treatment duration[91-93]. In certain combinations, daclatasvir allows the use of IFN-free combinations for those unable to tolerate IFN and have been shown effective in those who previously failed telaprevir/boceprevir regimens[93,94].

Across studies, the most frequently reported adverse events are diarrhea, headache and nasopharyngitis, all of which were reported to be mild. Less common adverse events include abdominal discomfort, malaise, constipation and back pain. No studies reported psychiatric symptoms or adverse events[91,93,94].

***Ledipasvir***

Ledipasvir, another NS5A inhibitor has also resulted in high rates of SVR among both previously treated as well as treatment naïve patients with HCV[95,96]. The rates of SVR ranged from 97%-99% across groups given combination therapy of ledipasvir and sofosbuvir, with and without RBV at 12 and 24 wk. Additional assessments indicate that ledipasvir–sofosbuvir regimens given for 8 wk is associated with a high rate of SVR among both previously treated and treatment naïve patients with HCV genotype 1 including those with cirrhosis. No additional benefit was associated with the addition of RBV to this combination or with extension of the duration of treatment to 12 wk[97,98] (Table 10).

The most common adverse events across studies were fatigue, headache, insomnia, and nausea[95]. The incidence of adverse events was lower among patients receiving ledipasvir–sofosbuvir alone than among those receiving ledipasvir–sofosbuvir plus RBV[95-98]. Patients in the groups that received ledipasvir– sofosbuvir plus RBV for 12 or 24 wk had higher rates of events known to be associated with ribavirin therapy-fatigue, insomnia, asthenia, rash, cough, pruritus, and anemia-than did those in the corresponding groups that received ledipasvir–sofosbuvir without RBV[95,96]. Few to no patients dropped out the study or discontinued due to adverse events, and in some cases, even those who discontinued still achieved a SVR[96]. Overall, no psychiatric adverse events were reported across studies and none led to discontinuation[95-98] (Table 11).

In summary, these new medications will shorten the duration of treatment and also allow IFN-free combination therapy, thus reducing dramatically the risk of neuropsychiatric symptoms and, in particular, depression.

**SUMMARY**

HCV infection is known to decrease HRQOL, an issue only exacerbated by various psychosocial factors and psychiatric illness. Antiviral therapy with HCV is often complicated by pre-existing depression as well as other psychiatric illnesses including schizophrenia, bipolar disorder and SUD. The common neuropsychiatric side effects- in particular depression- associated with IFN-based therapies made antiviral therapy problematic and often resulted in exclusion of people who had pre-existing depression or other psychiatric illnesses. However, various studies have shown that neuropsychiatric side effects can be successfully managed during IFN-based antiviral therapy and that people with pre- existing psychiatric illness can be treated successfully and achieve SVR within interdisciplinary care models that involve psychiatric health care providers. The use of interdisciplinary teams has been shown to increase the likelihood of treatment completion for patients with psychiatric illnesses. This approach must be fostered because IFN-free antiviral therapy will not be immediately available due to the prohibitively high cost of these medications. Furthermore, the cost will likely impact treatment viability in developing countries.

The development of new medication options for the treatment of HCV has provided additional opportunities for treatment of people with HCV who have- or are at risk for- psychiatric illness. For those who can tolerate the side effects of IFN and are compliant with treatment, the addition of telaprevir or simeprevir can significantly decrease treatment duration, and thereby decrease the likelihood of developing depressive and other psychiatric symptomatology. Moreover, sofosbuvir based regimens remain the most viable FDA approved drug at this time. New medications under development will allow IFN- free medication combinations and higher rates of SVR, with little to no risk of developing or exacerbating preexisting depressive symptoms.

**LIMITATIONS**

Despite new treatment options, there are several factors that should be considered. One consideration is that the use of newer Direct Acting Antiviral (DAA) medications such as telaprevir, boceprevir, simeprevir, sofosbuvir, ombitasvir and dasabuvir may be limited by drug to drug interactions (DDI). While studies identify minimal neuropsychiatric risks directly associated with the use of various DAAs, they can potentially interact with a variety of psychotropic agents causing unwanted adverse effects which may alternatively and indirectly affect treatment outcomes[99,100]. Triazolam, oral midazolam, St. John’s Wort, carbamazepine, Phenytoin, Phenobarbital, oxcarbazepine and pimozide, are among psychotropic medications known to be contraindicated with DAAs[99,100].

A second consideration is that medications under development may not be options for all genotypes of HCV or for those with severe liver disease. Furthermore, these medications are costly, with some estimated to be $1000/pill, and thus, may not be a viable option in less developed countries and/or families with low SES or lack of insurance for whom this cost is too great.

A final limitation of this review is that the vast majority of studies related to medications under development may have excluded patients with preexisting psychiatric diagnoses or those in historical underserved health disparity populations. So called “real world” clinical trials are necessary in order to assess the viability of these new medications in underserved populations. However, the shorter duration of antiviral therapy and the availability of IFN-free therapies hold great promise for the future of HCV treatment.

**REFERENCES**

1 **Marinho RT**, Barreira DP. Hepatitis C, stigma and cure. *World J Gastroenterol* 2013; **19**: 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703]

2 **Centers for Disease Control and Prevention.** Surveillance for Viral Hepatitis – United States, 2014. Available from: http: //www.cdc.gov/hepatitis/Statistics/2011Surveillance/Commentary.htm#hepC

3 **Chak E**, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. *Liver Int* 2011; **31**: 1090-1101 [PMID: 21745274 DOI: 10.1111/j.1478-3231.2011.02494.x]

4 **Wise M**, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. *Hepatology* 2008; **47**: 1128-1135 [PMID: 18318441 DOI: 10.1002/hep.22165]

5 **Butt AA**, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. *Hepatology* 2009; **50**: 387-392 [PMID: 19591128 DOI: 10.1002/hep.23000]

6 **Cheung RC**. Epidemiology of hepatitis C virus infection in American veterans. *Am J Gastroenterol* 2000; **95**: 740-747 [PMID: 10710068 DOI: 10.1111/j.1572-0241.2000.01854.x]

7 **Dominitz JA**, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, Stenhouse A, Kling MA, Hrushesky W, Zeilman C, Sontag S, Shah N, Ona F, Anand B, Subik M, Imperiale TF, Nakhle S, Ho SB, Bini EJ, Lockhart B, Ahmad J, Sasaki A, van der Linden B, Toro D, Martinez-Souss J, Huilgol V, Eisen S, Young KA. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. *Hepatology* 2005; **41**: 88-96 [PMID: 15619249 DOI: 10.1002/hep.20502]

8 **Briggs ME**, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, Wright TL. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. *Hepatology* 2001; **34**: 1200-1205 [PMID: 11732010 DOI: 10.1053/jhep.2001.29303]

9 **Ali SA**, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. *Int J Infect Dis* 2009; **13**: 9-19 [PMID: 18835208 DOI: 10.1016/j.ijid.2008.06.019]

10 **Mikocka-Walus AA**, Turnbull DA, Andrews JM, Moulding NT, Wilson IG, Harley HA, Hetzel DJ, Holtmann GJ. Psychological problems in gastroenterology outpatients: A South Australian experience. Psychological co-morbidity in IBD, IBS and hepatitis C. *Clin Pract Epidemiol Ment Health* 2008; **4**: 15 [PMID: 18500977 DOI: 10.1186/1745-0179-4-15]

11 **Weinstein AA**, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. *Psychosomatics* 2011; **52**: 127-132 [PMID: 21397104 DOI: 10.1016/j.psym.2010.12.019]

12 **Golden J**, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. *Gen Hosp Psychiatry* 2005; **27**: 431-438 [PMID: 16271658 DOI: 10.1016/j.genhosppsych.2005.06.006]

13 **Whitehead AJ**, Dobscha SK, Morasco BJ, Ruimy S, Bussell C, Hauser P. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C. *J Pain Symptom Manage* 2008; **36**: 39-45 [PMID: 18358690 DOI: 10.1016/j.jpainsymman.2007.08.013]

14 **Morasco BJ**, Huckans M, Loftis JM, Woodhouse J, Seelye A, Turk DC, Hauser P. Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. *Gen Hosp Psychiatry* 2010; **32**: 413-418 [PMID: 20633746 DOI: 10.1016/j.genhosppsych.2010.03.010]

15 **Morasco BJ,** Lovejoy TI, Turk DC, Crain A, Hauser P, Dobscha SK. Biopsychosocial factors associated with pain in Veterans with the hepatitis C virus. *J Behav Med* 2014; **37:** 902-911 [DOI: 10.1007/s10865-013-9549-y]

16 **Loftis JM**, Hauser P. Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient. *Dig Dis Sci* 2013; **58**: 2753-2755 [PMID: 23959213 DOI: 10.1007/s10620-013-2809-4]

17 **Rogal SS**, Winger D, Bielefeldt K, Rollman BL, Szigethy E. Healthcare utilization in chronic liver disease: the importance of pain and prescription opioid use. *Liver Int* 2013; **33**: 1497-1503 [PMID: 23758842 DOI: 10.1111/liv.12215]

18 **Loftis JM**, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. *J Psychosom Res* 2013; **74**: 57-63 [PMID: 23272989 DOI: 10.1016/j.jpsychores]

19 **Fireman M**, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. *Clin Infect Dis* 2005; **40 Suppl 5**: S286-S291 [PMID: 15768336 DOI: 10.1086/427442]

20 **Lehman CL**, Cheung RC. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. *Am J Gastroenterol* 2002; **97**: 2640-2646 [PMID: 12385453 DOI: 10.1111/j.1572-0241.2002.06042.x]

21 **Rowan PJ**, Al-Jurdi R, Tavakoli-Tabasi S, Kunik ME, Satrom SL, El-Serag HB. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. *J Clin Gastroenterol* 2005; **39**: 731-736 [PMID: 16082286]

22 **Nelligan JA**, Loftis JM, Matthews AM, Zucker BL, Linke AM, Hauser P. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. *J Clin Psychiatry* 2008; **69**: 810-816 [PMID: 18426262]

23 **Su J**, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. *Hepatology* 2010; **52**: 436-442 [PMID: 20683943 DOI: 10.1002/hep.23726]

24 **Hauser P**, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. *Mol Psychiatry* 2002; **7**: 942-947 [PMID: 12399946]

25 **Loftis JM,** Hauser P. Hepatitis C in Patients with Psychiatric Disease and Substance Abuse: Screening Strategies and Co-Management Models of Care. *Current Hepatitis Reports* 2003; **2:** 93-100 [DOI: 10.1007/s11901-003-0002-5]

26 **Sylvestre DL**, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, Kresina TF, Seeff L, Francis H. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. *J Urban Health* 2004; **81**: 719-734 [PMID: 15466851 DOI: 10.1093/jurban/jth153]

27 **Loftis JM**, Hauser P. The phenomenology and treatment of interferon-induced depression. *J Affect Disord* 2004; **82**: 175-190 [PMID: 15488246 DOI: 10.1016/j.jad.2004.04.002]

28 **Loftis JM**, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. *Drugs* 2006; **66**: 155-174 [PMID: 16451091]

29 **Loftis JM,** Hauser P. Treating Hepatitis C in Patients with Comorbid Psychiatric and Substance Use Disorders. *Directions in Psychiatry* 2008; **28:** 227-243

30 **Leutscher PD**, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S, Hellstrand K, Bech P. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. *Hepatology* 2010; **52**: 430-435 [PMID: 20683942 DOI: 10.1002/hep.23699]

31 **Dalgard O**, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. *Eur Addict Res* 2002; **8**: 45-49 [PMID: 11818693]

32 **Fried MW**, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

33 **Fried MW**. Side effects of therapy of hepatitis C and their management. *Hepatology* 2002; **36**: S237-S244 [PMID: 12407599 DOI: 10.1053/jhep.2002.36810]

34 **Hauser P,** Loftis JM, Dieperink E, Garcia-Tsao G, Rigsby M, Willenbring M and the Veteran Health Administration Hepatitis C Resource Center Program. Depression and Substance Use Disorders in Chronic Hepatitis C: Implications of New Guidelines and Experience in the VA Health Care System. *Fed Prac* 2004; **21:** 90-102

35 **Raison CL**, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiatry* 2005; **66**: 41-48 [PMID: 15669887]

36 **Angelino AF**, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. *Int Rev Psychiatry* 2005; **17**: 471-476 [PMID: 16401545 DOI: 10.1080/02646830500381567]

37 **Inder D**, Rehan HS, Yadav M, Manak S, Kumar P. IFN-α-2a (Interferon) and ribavirin induced suicidal attempt in a patient of chronic HCV: A rare case report. *Indian J Pharmacol* 2011; **43**: 210-211 [PMID: 21572662 DOI: 10.4103/0253-7613.77375]

38 **Hauser P**, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, Rifai A, Indest DW, Loftis JM. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. *Psychosomatics* 2009; **50**: 500-505 [PMID: 19855036 DOI: 10.1176/appi.psy.50.5.500]

39 **Loftis JM**, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. *Neurosci Lett* 2004; **365**: 87-91 [PMID: 15245784]

40 **Chainuvati S**, Khalid SK, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia-Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. *J Viral Hepat* 2006; **13**: 235-241 [PMID: 16611189 DOI: 10.111/j.1365-2893.2005.00681.x]

41 **Bini EJ**, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. *Am J Gastroenterol* 2005; **100**: 1772-1779 [PMID: 16086714 DOI: 10.1111/j.1572-0241.2005.41860.x]

42 **Anand BS,** Currie S, Dieperink, E, Bini EJ, Shen H, Ho SB, Wright T. Alcohol use and Treatment of Hepatitis C Virus: Results of a national Multicenter study. *Gastroenterology* 2006; **130:** 1607-1616

43 **Huckans M**, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. *Schizophr Bull* 2010; **36**: 165-172 [PMID: 18562341 DOI: 10.1093/schbul/sbn065]

44 **Huckans MS**, Blackwell AD, Harms TA, Hauser P. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. *Psychiatr Serv* 2006; **57**: 403-406 [PMID: 16525001]

45 **Fuller BE**, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. *Gen Hosp Psychiatry* 2011; **33**: 232-237 [PMID: 21601719 DOI: 10.1016/j.genhosppsych.2011.03.006]

46 **Huckans M**, Mitchell A, Pavawalla S, Morasco BJ, Ruimy S, Loftis JM, Rifai MA, Hauser P. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. *Antivir Ther* 2010; **15**: 111-119 [PMID: 20167997 DOI: 10.3851/IMP1493]

47 **Backmund M**, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. *Clin Infect Dis* 2004; **39**: 1540-1543 [PMID: 15546094 DOI: 10.1086/425361]

48 **Grebely J**, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, Dore GJ, Duncan F, Conway B. Reinfection with hepatitis C virus following sustained virological response in injection drug users. *J Gastroenterol Hepatol* 2010; **25**: 1281-1284 [PMID: 20594256 DOI: 10.1111/j.1440-1746.2010.06238.x]

49 **Loftis JM,** Morasco BJ, Menasco DJ, Fuchs D, Strater M, Hauser P. Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C. *Open Infect Dis J* 2010; **4**: 132-141 [PMID: 21151716]

50 **Patterson AL**, Morasco BJ, Fuller BE, Indest DW, Loftis JM, Hauser P. Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity? *Gen Hosp Psychiatry* 2011; **33**: 354-362 [PMID: 21762832 DOI: 10.1016/j.genhosppsych.2011.04.005]

51 **Loftis JM,** Matthews AM, Hauser P. Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management. *Drugs* 2006; **66:** 156-174

52 **Loftis JM**, Hauser P, Rifai MA. The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. *Brain Behav Immun* 2005; **19**: 271-22; author reply 271-22; [PMID: 15944066 DOI: 10.1016/j.bbi.2005.03.007]

53 **Loftis JM**, Morasco BJ, Hauser P. Depression and antiviral response to interferon-based therapy for hepatitis C virus infection. *Hepatology* 2011; **53**: 1413-1414 [PMID: 21480359 DOI: 10.1002/hep.24064]

54 **Gleason OC**, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. *J Clin Psychiatry* 2002; **63**: 194-198 [PMID: 11926717]

55 **Gleason OC**, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. *Prim Care Companion J Clin Psychiatry* 2005; **7**: 225-230 [PMID: 16308578]

56 **Galvão-de Almeida A**, Guindalini C, Batista-Neves S, de Oliveira IR, Miranda-Scippa A, Quarantini LC. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. *Gen Hosp Psychiatry* 2010; **32**: 401-405 [PMID: 20633744 DOI: 10.1016/j.genhosppsych.2010.03.001]

57 **Schaefer M**, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. *J Hepatol* 2005; **42**: 793-798 [PMID: 15885349 DOI: 10.1016/j.jhep.2005.01.020]

58 **Morasco BJ**, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. *J Affect Disord* 2007; **103**: 83-90 [PMID: 17292481 DOI: 10.1016/j.jad.2007.01.007]

59 **Raison CL**, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. *Aliment Pharmacol Ther* 2007; **25**: 1163-1174 [PMID: 17451562 DOI: 10.1111/j.1365-2036.2007.03316.x]

60 **Morasco BJ**, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. *Psychosomatics* 2010; **51**: 401-408 [PMID: 20833939 DOI: 10.1176/appi.psy.51.5.401]

61 **Dalton SO**, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. *Arch Intern Med* 2003; **163**: 59-64 [PMID: 12523917 DOI: 10.1001/archinte.163.1.59]

62 **Weinrieb RM**, Auriacombe M, Lynch KG, Chang KM, Lewis JD. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. *J Clin Psychiatry* 2003; **64**: 1502-1510 [PMID: 14728113]

63 **Hejny C**, Sternberg P, Lawson DH, Greiner K, Aaberg TM. Retinopathy associated with high-dose interferon alfa-2b therapy. *Am J Ophthalmol* 2001; **131**: 782-787 [PMID: 11384576 DOI: 10.1016/S0002-9394(01)00836-4]

64 **Ozcanli T**, Unsalver B, Ozdemir S, Ozmen M. Sertraline- and mirtazapine-induced severe neutropenia. *Am J Psychiatry* 2005; **162**: 1386 [PMID: 15994730 DOI: 10.1176/appi.ajp.162.7.1386]

65 **Scheft H**, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. *Clin Infect Dis* 2005; **40 Suppl 5**: S292-S296 [PMID: 15768337 DOI: 10.1086/427443]

66 **Sockalingam S**, Abbey SE. Managing depression during hepatitis C treatment. *Can J Psychiatry* 2009; **54**: 614-625 [PMID: 19751550]

67 **Knott A**, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. *Am J Gastroenterol* 2006; **101**: 2254-2262 [PMID: 17032190 DOI: 10.1111/j.1572-0241.2006.00731.x]

68 **McHutchison JG**, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; **362**: 1292-1303 [PMID: 20375406 DOI: 10.1056/NEJMoa0908014]

69 **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]

70 **U.S. Food and Drug Administration (FDA).** Viral Hepatitis Therapies: Approved Treatments for Hepatitis C. [retrieved 2014 Mar 28]. Available from: http: //www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm151494.htm

71 **Vertex Pharmaceuticals Incorporated.** INCIVEKTM (telaprevir) Prescribing information. [retrieved 2014 Mar 28]. Available from: http: //www.accessdata.fda.gov/drugsatfda\_docs/label/2012/201917s007lbl.pdf

72 **Kumada H**, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. *J Hepatol* 2012; **56**: 78-84 [PMID: 21827730 DOI: 10.1016/j.jhep.2011.07.016]

73 **Hézode C**, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; **360**: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650]

74 **Sherman KE**, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011; **365**: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]

75 **Bacon BR**, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

76 **Poordad F**, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

77 **Kwo PY**, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2010; **376**: 705-716 [PMID: 20692693 DOI: 10.1016/S0140-6736(10)60934-8]

78 **Merck Sharp and Dohme Corp.** Victrelis/ Boceprevir Safety and Prescribing information. 2014. [retrieved 2014 Jul 17]. Available from: http: //victrelis.com/boceprevir/victrelis/consumer/hepatitis-c-treatment.jsp

79 **Zeuzem S**, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. *Gastroenterology* 2014; **146**: 430-41.e6 [PMID: 24184810 DOI: 10.1053/j.gastro.2013.10.058]

80 **Fried MW**, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. *Hepatology* 2013; **58**: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]

81 **Jacobson IM**, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet* 2014; **384**: 403-413 [PMID: 24907225 DOI: 10.1016/S0140-6736(14)60494-3]

82 **Manns M**, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2014; **384**: 414-426 [PMID: 24907224 DOI: 10.1016/S0140-6736(14)60538-9]

83 **Kumada H**, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. *Hepatol Res* 2015; **45**: 501-513 [PMID: 24961662 DOI: 10.1111/hepr.12375]

84 **Gane EJ**, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med* 2013; **368**: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]

85 **Jacobson IM**, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 2013; **368**: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]

86 **Kowdley KV**, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2013; **381**: 2100-2107 [PMID: 23499440 DOI: 10.1016/S0140-6736(13)60247-0]

87 **Lawitz E**, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *Lancet Infect Dis* 2013; **13**: 401-408 [PMID: 23499158 DOI: 10.1016/S1473-3099(13)70033-1]

88 **Zeuzem S**, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014; **370**: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]

89 **Andreone P**, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. *Gastroenterology* 2014; **147**: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045]

90 **Herbst DA**, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. *Expert Opin Investig Drugs* 2013; **22**: 1337-1346 [PMID: 23931586 DOI: 10.1517/13543784.2013.826189]

91 **Chayama K**, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology* 2012; **55**: 742-748 [PMID: 21987462 DOI: 10.1002/hep.24724]

92 **Pol S**, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. *Lancet Infect Dis* 2012; **12**: 671-677 [PMID: 22714001 DOI: 10.1016/S1473-3099(12)70138-X]

93 **Sulkowski MS**, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med* 2014; **370**: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]

94 **Suzuki Y**, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. *J Hepatol* 2013; **58**: 655-662 [PMID: 23183526 DOI: 10.1016/j.jhep.2012.09.037]

95 **Afdhal N**, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]

96 **Afdhal N**, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]

97 **Kowdley KV**, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014; **370**: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]

98 **Lawitz E,** Poordad F, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchinson J, Membreno FE. Sofosbuvir and ledipasvir fi xed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. *Lancet* 2014; **383:** 515-523 [DOI: 10.1016/S0140-6736(13)62121-2]

99 **Sockalingam S**, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. *BMC Gastroenterol* 2013; **13**: 86 [PMID: 23672254 DOI: 10.1186/1471-230X-13-86]

100 **Pockros PJ**. New direct-acting antivirals in the development for hepatitis C virus infection. *Therap Adv Gastroenterol* 2010; **3**: 191-202 [PMID: 21180601 DOI: 10.1177/1756283X10363055]

**P- Reviewer:** El-Bendary M, Inoue K, Sertoglu E, Tsoulfas G

**S- Editor:** Song XX **L- Editor:** **E- Editor:**

**Table 1 Hepatitis C and pain related diagnoses**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | |
| Ref. | N | Design | Assessments | Outcome |
| Whitehead *et al*[13] | 8224 | Retrospective Chart review | Clinical Data, diagnoses, and medical history | Pain and SUD diagnoses were common among HCV patients, and opioids were frequently prescribed |
| Morasco *et al*[14] | 49 | Subjective Assessment | Clinical Interview, Medical records BDI-II, SDS, SF-36 | Psychosocial variables, particularly depression severity, account for variance in pain intensity and pain functioning |
| Rogal *et al*[17] | 1286 | Retrospective Cohort Study | Self-Report, Symptom checklist and Medical Record | There is a high prevalence of pain and opioid use in patients with chronic liver disease. |
| Morasco *et al*[15] | 119 | Subjective Assessment | TLFB, Self-Report; MPI, BDI-II, PCS, CPSS, CPCI, SCID | Biopsychosocial factors significantly affected pain severity and pain interference in patients with HCV |

HCV: Hepatitis C virus; SUD: Substance use disorder; BDI-II: Beck depression inventory, second edition; SF-12: Short form 12; MPI: Multidimensional pain inventory; PCS: Pain catastrophizing scale; CPSS: Chronic pain self efficacy scale; CPCI: Chronic pain coping inventory; SCID: Structured clinical interview for DSM IV.

**Table 2 Hepatitis C and psychiatric comorbidities**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | |
| Ref. | N | Design | Assessments | Outcome |
| Lehman *et al*[20] | 120 | Subjective Assessment | BDI-II, ASI, PCL, AUDIT, Medical Records | Clinically significant levels of depression anxiety, PTSD and alcohol-related problems were observed in patients with HCV |
| Fireman *et al*[19] | 293 | Prospective Assessment | AUDIT-C, BDI-II | Psychiatric and substance use disorders are highly prevalent among Veterans with chronic HCV |
| Rowan *et al*[21] | 62 | Subjective Assessment | SF-36 | Psychosocial factors, especially depression, are strong indicators of impaired HRQOL for HCV-infected Veterans |
| Bini *et al*[41] | 4084 | Prospective cohort study | Eligibility for IFN therapy | The majority of Veterans were not considered suitable candidates for HCV treatment because of substance use disorders, psychiatric disease, and comorbid medical disease |
| Mikocka-Walus *et al*[10] | 139 | Cross-Sectional assessment | HADS, SCL-90, SF-12, disease severity assessments | Patients with HCV had significantly higher prevalence of depression and lower HRQOL than patients with IBD and IBS, and the general population |
| Nelligan *et al*[22] | 881 | Subjective Assessment | BDI-II; Medical Records | Rates of depression are high among Veterans with HCV and persist among those with antidepressant prescriptions |
| Weinstein *et al*[11] | 878 | Retrospective chart review | Clinical and demographic data, medical history | Individuals with HCV have a higher prevalence of depression than HBV and NAFLD patients and the general population |

BDI-II: Beck depression inventory, second edition; ASI: Anxiety severity index; PCL: Post traumatic stress disorder check-list; AUDIT: Alcohol use disorders identification test; HCV: Hepatitis C virus; SF-12: Short form 12; HRQOL: Health related quality of life; IFN: Interferon; IBD: Irritable bowel disease; IBS: Irritable bowel syndrome; SCL-90: Symptom checklist 90; NAFLD: Non-alcoholic fatty liver disease.

**Table 3 Neuropsychiatric side effects of interferon and interferon-induced depression**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ref. | N | Design | Treatment | Outcomes |
| Fried *et al*[32] | -- | Retrospective Literature Review | PEGIFN-α -2a and 2b with RBV,  IFN-α -2b/RBV | Across studies, Depression occurred in 22% of those treated with PEGIFN-α-2a/RBV, 31% with PEGIFN-α -2b/RBV and 30%-34% of those treated with standard IFN treatment (PEGIFN-α 2b/RBV) |
| Fried *et al*[33] | 1121 | Randomized clinical trial | PEGIFN-α -2a/RBV, IFN-α- 2b/RBV,  PEGIFN-α -2a | Patients treated with PEGIFN-α-2a plus RBV or placebo had a lower incidence of depression than those treated with IFN-α -2b plus RBV (22% and 20% *vs* 30%) |
| Loftis and Hauser[16] | -- | Retrospective Literature Review | IFN-α, IFN-β, and IFN-γ | Symptoms of depression induced by IFN therapy is common and can limit the treatment utility, often necessitate discontinuation of IFN treatment or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed |
| Hauser *et al*[34] | -- | Retrospective Literature Review | IFN-α | Neuropsychiatric side effects such as depression, may develop as a result of IFN therapy and lead to lower HRQOL, dose reductions or discontinuation |
| Raison *et al*[35] | 162 | Longitudinal assessment | PEGIFN- α -2b | Moderate to severe depressive symptoms occurred frequently during PEGIFN/RBV treatment and was predicted by baseline depression scores and higher doses of RBV |
| Inder *et al*[37] | 1 | Retrospective Case Report | IFN-α-2a/ RBV | Suicide attempt occurred during IFN-α treatment, improvements were only seen with drug dechallenge. Following re-challenge with combination therapy, patient again experienced suicidal ideation |
| Loftis *et al*[18] | 32 | Prospective Cohort study | PEGIFN-α-2a and 2b/RBV | IFN therapy results in a significant increase in depressive symptoms over time, with neuro-vegetative and somatic symptoms of depression increasing more than other depressive symptoms |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; IFN: Interferon; HRQOL: Health related quality of life.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 4 Antiviral treatment response rates in patients with psychiatric and substance use disorders comorbidities** | | | | |
| Ref. | N | Design | Treatment | Outcomes |
| Dalgard *et al*[31] | 27 | Longitudinal assessment | IFN-α-2a | Rate of reinfection was not significantly different among IVDUers treated for HCV as compared to non IVDUers despite reinitiation of injection drug use in 33% of IVDUers |
| Loftis *et al*[27] | 39 | Prospective Cohort Study | IFN-α-2b/RBV | Gender, past history of MDD, and past history of SUD were not significantly associated with response rates |
| Backmund *et al*[47] | 18 | Longitudinal  assessment | IFN-α-2a, IFN-α-2a/RBV | IVDUers can be reinfected after treatment for HCV infection, but the reinfection rate is minimal and should not jeopardize the potential benefit for most patients |
| Chainuvati *et al*[40] | 647 | Retrospective database review | Eligibility/ treatment rates for Interferon therapy | Therapy completion and SVR rates are similar among Veterans with and without psychiatric or SUDs, challenging the perception that adherence is worse as a result of psychiatric co-morbidities |
| Anand *et al*[42] | 4061 | Longitudinal assessment | IFN-α-2b/RBV | Patients with and without mild to moderate alcohol use had comparable completion and SVR rates to antiviral treatment |
| Hauser *et al*[39] | 55 | Retrospective chart review | Completion rates of antiviral therapy in patients with and without MDD | People with MDD had completion and SVR rates similar to those without psychiatric illness. Patients with MDD can be safely and effectively treated with antiviral therapy provided that they are on antidepressant medications |
| Huckans *et al*[43] | 60 | Retrospective Chart Review | PEGINF/RBV, IFN/RBV | Patients with schizophrenia experience similar rates of psychiatric symptoms on and off antiviral therapy |
| Grebley *et al*[48] | 58 | Prospective longitudinal follow up | IFN-α-2b/RBV, PEGIFN-α- 2a, PEGIFN-α-2b | Rate of reinfection following treatment for HCV infection among current and former IVDUers engaged in a multidisciplinary program is low |

IFN-α: Interferon alpha; IVDUer: Intravenous drug user; RBV: Ribavirin; MDD: Major depressive disorder; SUD: Substance use disorder; SVR: Sustained virologic response; PEGINF: Peglyated interferon (Peginterferon).

**Table 5 Antidepressant treatment of interferon- induced depression**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | N | Design | Antidepressant | | Outcomes |
| Gleason *et al*[54] | 15 | Open-label clinical trial | citalopram | IFN-induced MDD in patients with HCV may be effectively and safely treated with citalopram | |
| Hauser *et al*[24] | 39 | Prospective Cohort study | BDI-II; IFN-α- 2b/RBV | 33% of patients receiving IFN therapy develop IFN-induced MDD. There were no differences in age, gender, past history of MDD, or substance use between those who became depressed and those who did not. Of those who developed IFN-induced depression most responded to antidepressant treatment allowing continuation of antiviral therapy | |
| Loftis and Hauser 2004[27] | -- | Retrospective Literature Review | IFN-α, IFN-β, and IFN-γ | Depression induced by IFN therapy is common and can limit treatment utility and necessitate discontinuation of antiviral treatment. However, the use of psychopharmacologic agents allows treatment continuation | |
| Angelino *et al*[36] | -- | Retrospective Literature review | IFN-α | Treatment with IFN may provoke episodes of depression however, several standard treatments for depression can mediate these symptoms, suggesting that depression may not be a barrier to effective treatment | |
| Gleason *et al* [55] | 18 | Open-label clinical trial | escitalopram | IFN-induced MDD in patients with HCV may be effectively and safely treated with escitalopram | |

HCV: Hepatitis C virus; IFN: Interferon; RBV: Ribavirin; MDD: Major depressive disorder; BDI: Beck depression inventory.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 6 Antidepressant prophylaxis** | | | | |
| Ref. | N | Design | Antidepressant | Outcomes |
| Angelino *et al*[36] | -- | Retrospective Literature review | citalopram; fluvoxamine | Prophylactic antidepressants might be well-considered for patients with a family history of- or previous episodes of- depression |
| Schaefer *et al*[57] | 33 | Prospective clinical trial | citalopram | Pre-treatment of psychiatric patients with citalopram significantly reduced the incidence of IFN-induced MDD during the first 6 mo of antiviral treatment |
| Raison *et al*[59] | 61 | Double-blind,  placebo-controlled clinical trial | paroxetine | Data support the use of antidepressant pre-treatment in HCV patients with elevated depressive symptoms at baseline |
| Morasco *et al*[58] | 33 | Double-blind,  placebo-controlled clinical trial | paroxetine | A prophylactic approach to reduce IFN-α -induced depression may not be indicated in patients with HCV |
| Galvao-de Almeida *et al*[56] | -- | Retrospective Literature Review | citalopram, paroxetine, escitalopram | Antidepressant prophylaxis may blunt the magnitude of depressive symptoms in HCV patients and raise the rates of treatment completion in those with psychiatric diagnosis. |
| Morasco *et al*[60] | 39 | Double-blind,  placebo-controlled clinical trial | citalopram | Citalopram is not superior to placebo in preventing IFN-induced MDD. |

IFN: Interferon; MDD: Major depressive disorder; HCV: Hepatitis C virus; BDI-II: Beck depression inventory-II.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 7 Telaprevir** | | | | | |
| Ref. | N | Design | Treatment | Population | Outcome |
| Hezode *et al*[73] | 334 | Phase 2 Randomized Clinical Trial | Telaprevir  PEGIFN/RBV | HCV genotype 1- treatment naïve | Telaprevir groups had significantly higher rates of SVR than PEGIFN/RBV alone. Depression occurred in 20-23% of patients and was not significantly different across groups |
| McHutchinson *et al*[68] | 115 | Randomized Clinical Trial | Telaprevir | HCV genotype 1 – previous non-responders to PEGINF/RBV | Re-treatment with telaprevir was more effective than PEGIFN-α/RBV alone. Depression occurred in 11-17% of participants. |
| Zeuzem *et al*., [69] | 663 | Phase III Randomized Clinical Trial | telaprevir,  PEGIFN- α-2a/ RBV | HCV genotype 1 - previous non responders, partial responders and relapsers | Telaprevir in combination with PEGIFN/ RBV significantly improved rates of SVR and, as compared with PEGIFN/RBV alone showed no increase in neuropsychiatric side effects |
| Kumada *et al*[72] | 1126 | Multicenter Randomized Clinical Trial | Telaprevir,  PEGIFN-α-2b/RBV | HCV genotype 1- treatment naive | Triple therapy with telaprevir-based regimen resulted in higher SVR with shorter duration. Depression was not listed as an adverse event. |
| Sherman *et al*[74] | 540 | Randomized Clinical Trial | telaprevir  PEGIFN-α-2a/RBV | HCV genotype 1 – treatment naïve | Combination therapy with telaprevir for 24 weeks was non inferior to standard therapy for 48 weeks. 53% of patients experienced psychiatric symptoms |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 8 Boceprevir** | | | | | |
| Ref. | N | Design | Treatment | Population | Outcome |
| Kwo *et al*[77] | 520 | Two part randomized clinical trial | Boceprevir  PEGIFN-α-2b/RBV | chronic HCV genotype 1- treatment naïve | Boceprevir has the potential to double the SVR rate compared with standard treatment alone. Insomnia was the only psychiatric illness documented |
| Bacon *et al*[75] | 403 | Placebo controlled, Randomized clinical trial | boceprevir,  PEGIFN-α-2b/RBV | Retreatment of patients with chronic HCV genotype 1 infection | Boceprevir resulted in significantly higher rates of SVR. Significant onset of depression was not indicated |
| Poordad *et al*[76] | 1097 | Double blind, placebo controlled randomized clinical trial | Boceprevir  PEGIFN-α-2b/RBV | Chronic HCV genotype 1- treatment naïve | Boceprevir significantly increased the rates of SVR. Insomnia was the only psychiatric condition identified as an adverse event. |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 9 Simeprevir** | | | | | |
| Ref. | N | Design | Treatment | Population | Outcome |
| Fried *et al*[80] | 338 | Phase 2b double blind, placebo controlled randomized clinical trial | simeprevir  PEGIFN-α-2a/RBV | Treatment-naıve patients with HCV genotype 1 infection. | Simeprevir in combination with PEGIFN/ RBV significantly improved SVR rates and shortened therapy duration. Depression occurred in 10.4% of patients on simeprevir and 18.2% on standard treatment |
| Zeuzem *et al*[79] | 396 | Placebo controlled, randomized clinical trial | simeprevir, PEGIFN-α2a/RBV | patients with HCV genotype-1 infection previously treated with PEGIFN/RBV | 12, 24, or 48 wk simeprevir with 48 wk PEGIFN/ RBV significantly increased rates of SVR and was generally well tolerated. Depression occurred in 2/396 simeprevir patients |
| Jacobson *et al*[81] | 394 | Phase 3, randomized, double blind, placebo controlled multicenter clinical trial | simeprevir,  PEGIFN-α-2a/RBV | Treatment naïve patients with HCV genotype 1 | Simeprevir with PEGIFN-α 2a/ RBV shortens therapy without worsening the adverse event profiles associated with PEGIFN. |
| Manns *et al*[82] | 257 | Phase 3 multicenter randomized, placebo controlled clinical trial | simeprevir  PEGIFN-α-2a or 2b/RBV | Treatment-naive patients with HCV genotype 1 infection. | Addition of simeprevir to PEGIFN-α 2a or PEGIFN-α 2b plus RBV improved SVR without worsening the known adverse events associated with peginterferon |
| Kumada *et al*[83] | 79 | Open label non comparative multicenter trial | simeprevir  PEGIFN-α-2b/RBV | HCV genotype 1 -treatment-naïve or had previously received interferon (IFN)-based therapy | Simeprevir combined with PEGIFN-α-2b/RBV was effective across both groups. One patient in the control group receiving standard therapy alone discontinued due to grade 2 depression. |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 10 Sofosbuvir** | | | | | |
| Ref. | N | Design | Treatment | Population | Outcome |
| Kowdley *et al*[86] | 316 | Multicenter, Open label, phase 2 clinical trial | sofosbuvir -2a PEGIFN-α-2a /RBV | HCV genotype 1- non-cirrhotic treatment-naive, patients | SVR occurred in 90% of patients treated with sofosbuvir and PEGIFN/RBV for 12 wk. Depression occurred in 8-16% of patients across all groups but was not a primary reason for discontinuation |
| Lawitz *et al*[87] | 147 | Two-cohort, phase 2 , placebo controlled, clinical trial | sofosbuvir  PEGIFN /RBV | Treatment-naive patients with genotype 1–3 HCV infection. | SVR occurred in 90% of patients treated with sofosbuvir and PEGIFN/RBV and the side effects profile was similar to that of PEGIFN/RBV and did not include depression. Depression was not a significant adverse event in this study. |
| Jacobson *et al*[85] | 240 | phase 3 randomized placebo controlled clinical trials | sofosbuvir  RBV | Chronic HCV genotype 2 or 3 previously unable to be treated with IFN, or previously treated with IFN-based therapies | Sofosbuvir and RBV was effective at 12 wk for genotype 2 and 16 wk for genotype 3. Premature discontinuation of the study drug due to adverse events was uncommon in all groups. Depression was not a significant adverse event in this study |
| Gane *et al*[84] | 75 | Open label randomized clinical trial | sofosbuvir,  RBV | HCV genotype 2 or 3 infection. with no response to prior treatment or with no prior treatment | Sofosbuvir plus RBV for 12 wk was effective for patients with genotype 1, 2, or 3 infections. Insomnia occurred in 30%-67% of participants across groups and was the only significant psychiatric symptom to develop during treatment |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response; IFN: Interferon.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 11 Newer medications and interferon free therapies** | | | | | |
| Ref. | N | Design | Treatment | Population | Outcome |
| Pol *et al*[92] | 48 | Double blind parallel group, dose finding phase 2a randomized, placebo controlled clinical trial | daclatasvir  PEGIFN-α-2a/RBV | HCV genotype 1 - treatment-naive  (without cirrhosis) | Daclatasvir increases the antiviral potency of PEGIFN/RBV without increasing the side effects profile. Psychiatric adverse events were not significant in this study |
| Chayama *et al*[91] | 10 | Open label phase 2a clinical trial | daclatasvir asunaprevir | Chronic HCV genotype 1b -previous null responders to PegINF/RBV | Dual therapy with daclatasvir and asunaprevir alone can achieve high rates of SVR in difficult-to-treat patients and has minimal side effects |
| Herbst *et al*[90] | -- | Retrospective Literature Review of phase 1 to phase 3 clinical trials | daclatasvir | All genotypes; treatment naive and experienced cohorts | Daclatasvir has a potent antiviral effect and clinical efficacy across genotypes and in both treatment naive and experienced cohorts with no evidence of psychiatric adverse events. |
| Suzuki *et al*[94] | 43 | Open label phase 2a clinical trial | daclatasvir asunaprevir | HCV genotype 1b for patients with limited treatment options including those with complications of depression | Dual therapy with daclatasvir and asunaprevir was well tolerated and achieved high SVR rates. The adverse event profile was favorable; no psychiatric abnormalities were reported |
| Zeuzem *et al*[88] | 394 | Phase 3 placebo controlled randomized clinical trial | ABT-450 ritonavir (ABT-450/r), ombitasvir  (ABT-267)  dasabuvir  (ABT-333)  RBV | Retreatment of HCV in patients who were previously treated with peginterferon–ribavirin | Rates of response to a 12-wk IFN-free combination regimen were more than 95%. Psychiatric adverse events were not reported |
| Andreone *et al*[89] | 179 | Phase 3 open label randomized clinical trial | ABT-450,  ritonavir, ombitasvir, dasabuvir  RBV | HCV genotype 1b – treatment experienced patients | ABT- 450, ritonavir, Ombitasvir, and Dasabuvir, with or without RBV, produced a high rate of SVR. Both regimens were well tolerated with minimal adverse events |
| Sulkowski *et al*[93] | 167 | Two part, Open label clinical trial | daclatasvir sofosbuvir | HCV genotype 1, 2, or 3 | Daclatasvir plus sofosbuvir was associated with high rates of SVR. Psychiatric problems were not listed as significant adverse events |
| Afdhal *et al*[96] | 865 | Phase 3, open-label randomized clinical trial | ledipasvir sofosbuvir  RBV | HCV genotype 1- treatment naive | Ledipasvir–sofosbuvir with or without RBV for 12 or 24 weeks was highly effective. The most common adverse events were fatigue, headache, Insomnia, and nausea |
| Lawitz *et al*[98] | 100 | Open label randomized clinical trial | sofosbuvir ledipasvir  RBV | HCV genotype 1 - treatment-naive or previously treated with a protease-inhibitor regimen | Sofosbuvir-ledipasvir alone or with RBV has the potential to cure most patients with genotype-1. Psychiatric symptoms were not a listed as significant adverse events |
| Afdhal *et al*[95] | 440 | Phase 3, randomized, open-label clinical trial | ledipasvir sofosbuvir  RBV | HCV genotype 1 – previously treated | Treatment with ledipasvir and sofosbuvir resulted in high rates of SVR. Neuropsychiatric side effects were minimal, but were observed more frequently among groups with the RBV-containing regimen than ledipasvir sofosbuvir alone |
| Kowdley *et al*[97] | 647 | Phase 3, open label clinical trial | sofosbuvir ledipasvir | HCV genotype 1 – treatment naive | Ledipasvir–sofosbuvir was associated with a high rate of SVR. Adverse events were more common in the group that received RBV. No additional benefit was associated with the inclusion of RBV |

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response; IFN: Interferon.